Abstract
Cambridge Antibody Technology (CAT) won its High Court battle against healthcare company Abbott over the level of royalties due on sales of the potential blockbuster drug Humira. CAT argued successfully that it was due a royalty of just over 5 per cent of sales, rather than the 2 per cent that Abbott had been paying. It is believed that CAT is due back payments from Abbott as well as future royalty payments at the higher rate on sales predicted to rise to over US$2bn per year.
Article PDF
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wilkinson, J., Dorey, F. Legal and regulatory update. J Commer Biotechnol 11, 279–288 (2005). https://doi.org/10.1057/palgrave.jcb.3040128
Published:
Issue Date:
DOI: https://doi.org/10.1057/palgrave.jcb.3040128